- Total revenue for Q1 2025 was $69.2 million, marking a 55% increase from the prior year.
- PROCEPT BioRobotics (PRCT, Financial) sold 43 new robotic systems in the U.S., expanding the total install base to 547 systems.
- Full-year 2025 revenue guidance increased to $323 million, signaling 44% growth over the previous year.
PROCEPT BioRobotics (PRCT) reported robust financial results for the first quarter of 2025, with total revenue reaching $69.2 million, a 55% increase from the same quarter in the previous year. The company showcased impressive growth in its U.S. market, notably with handpiece and consumables revenue rising 61% to $38.0 million, and system revenue increasing 31% to $18.7 million. International revenue also saw significant growth, doubling to $8.9 million.
The company sold 43 new robotic systems in the U.S. during the quarter, bringing its total install base in the country to 547 systems. This expansion helped drive an improvement in gross margin, which rose to 64% from 56% year-over-year. Despite a net loss of $24.7 million, this was an improvement over the $26.0 million loss recorded in the same period last year.
Looking ahead, PROCEPT has raised its 2025 revenue guidance to $323 million, representing a 44% growth, and anticipates achieving a full-year gross margin of approximately 64.5%. This revised guidance reflects the company's confidence in continuing its growth trajectory, particularly with increasing adoption of its Aquablation therapy and new system placements largely driven by Integrated Delivery Networks (IDNs).
